China National Medicines Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Guotao Tian
Chief executive officer
CN¥2.0m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 3yrs |
| CEO ownership | n/a |
| Management average tenure | 4.8yrs |
| Board average tenure | 3.1yrs |
Recent management updates
Recent updates
Investors Could Be Concerned With China National Medicines' (SHSE:600511) Returns On Capital
Mar 12
China National Medicines (SHSE:600511) Has A Rock Solid Balance Sheet
Feb 18Returns On Capital Signal Tricky Times Ahead For China National Medicines (SHSE:600511)
Dec 01We Think China National Medicines (SHSE:600511) Can Manage Its Debt With Ease
Nov 12The China National Medicines Corporation Ltd. (SHSE:600511) Third-Quarter Results Are Out And Analysts Have Published New Forecasts
Oct 25China National Medicines Corporation Ltd.'s (SHSE:600511) Prospects Need A Boost To Lift Shares
Sep 26Calculating The Fair Value Of China National Medicines Corporation Ltd. (SHSE:600511)
Sep 10Returns On Capital At China National Medicines (SHSE:600511) Paint A Concerning Picture
Jul 28China National Medicines Corporation Ltd.'s (SHSE:600511) Low P/E No Reason For Excitement
Jun 24China National Medicines (SHSE:600511) Has Announced That It Will Be Increasing Its Dividend To CN¥0.854
Jun 07Is China National Medicines (SHSE:600511) Using Too Much Debt?
Jun 05Calculating The Fair Value Of China National Medicines Corporation Ltd. (SHSE:600511)
May 21Capital Allocation Trends At China National Medicines (SHSE:600511) Aren't Ideal
Apr 10China National Medicines (SHSE:600511) Could Easily Take On More Debt
Feb 28CEO
Guotao Tian (53 yo)
Mr. Guotao Tian was Deputy General Manager of China National Medicines Corporation Ltd. from August 01, 2021. Mr. Tian is General Manager of China National Medicines Corporation Ltd.from May 31, 2022 and...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Director | 3yrs | CN¥2.00m | no data | |
| Chief Financial Officer | 1.6yrs | CN¥1.20m | no data | |
| General Counsel | 4.8yrs | CN¥1.20m | no data | |
| Deputy General Manager | 5.3yrs | CN¥1.60m | no data | |
| Deputy General Manager | 5.3yrs | CN¥1.40m | no data | |
| Deputy General Manager | 5.3yrs | CN¥1.40m | no data | |
| Accounting Supervisor | no data | no data | no data | |
| Deputy Secretary of the Party Committee | no data | CN¥371.90k | no data |
Experienced Management: 600511's management team is considered experienced (4.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Director | 3.1yrs | CN¥2.00m | no data | |
| Independent Director | 3.1yrs | CN¥200.00k | no data | |
| Independent Director | 3.1yrs | CN¥200.00k | no data | |
| Director | 6yrs | no data | no data | |
| Acting Chairman | 3.1yrs | CN¥2.00m | no data |
Experienced Board: 600511's board of directors are considered experienced (3.1 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/23 05:48 |
| End of Day Share Price | 2025/05/23 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
China National Medicines Corporation Ltd. is covered by 15 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yanyin Zhu | China International Capital Corporation Limited |
| Ying Luo | China Merchants Securities Co. Ltd. |
| Sophia Zhang | China Stock Investment Research Co. Ltd. (GZ500..com) |